Article
Spectrum's Rolontis hits another setback as FDA faces COVID-19 plant inspection backlog
Rating:
0.0
Views:
108
Likes:
1
Library:
1
The COVID-19 pandemic has disrupted another biopharma company's plan to launch a new medicine. This time, it's Spectrum Pharmaceuticals' neutropenia candidate Rolontis. The reason? The company licensed the med from South Korea's Hanmi, and FDA officials haven't been able to get to Korea for a final plant inspection.
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value